FDA-approved: for type 2 diabetes since 2010 and for chronic weight management since 2014 (including adolescents aged 12 and over who weigh more than 60 kg and have obesity, for the weight-management product), with generic versions of liraglutide approved from 2024.Source: FDA: Drugs@FDA — VICTOZA (NDA022341), original approval · United States · Decision January 25, 2010
Source: FDA: FDA-approved label — VICTOZA (NDA022341): type 2 diabetes and cardiovascular indications · United States · In force January 30, 2025
Source: FDA: Drugs@FDA — SAXENDA (NDA206321), original approval · United States · Decision December 23, 2014
Source: FDA: FDA-approved label — SAXENDA (NDA206321): chronic weight management, adults and patients aged 12 years and older over 60 kg with obesity · United States · In force February 25, 2026
Source: FDA: Drugs@FDA — liraglutide injection (ANDA215503), first generic approval · United States · Decision December 23, 2024